Skip to main content

Centessa Pharmaceuticals PLC (CNTA)

NASDAQ: CNTA · IEX Real-Time Price · USD
16.93 -0.07 (-0.41%)
Oct 25, 2021 4:00 PM EDT - Market closed
Market Cap1.52B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out89.90M
EPS (ttm)-3.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume52,048
Open16.80
Previous Close17.00
Day's Range16.10 - 17.19
52-Week Range13.34 - 26.90
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 16, 2021

About CNTA

Centessa Pharmaceuticals was conceived by combining the primary strengths of the asset-centric model with the benefits of diversification and scale typically attributed to traditional large R&D organizations. The asset-centric model refers to single-purpose companies which are focused on developing a single program or programs associated with a single biological pathway. We have implemented this reimagined approach to R&D by initially combining a curated portfolio of ten wholly-owned asset-centric companies, which we refer to as the Centessa Su...

IndustryBiotechnology
IPO DateMay 28, 2021
CEOSaurabh Saha, M.D., Ph.D.
Employees34
Stock ExchangeNASDAQ
Ticker SymbolCNTA
Full Company Profile

Financial Performance

Financial Statements

News

Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Or...

NEW YORK & BOSTON & LONDON--(BUSINESS WIRE)--Today, Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger announced a collaboration to discover novel orexin receptor agonists.

Other symbols:SDGR
1 week ago - Business Wire

Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital

~ New $300 million facility, combined with Company's cash balance as of June 30, 2021, provides access to over $900 million to advance development programs and enable pursuit of strategic business devel...

3 weeks ago - GlobeNewsWire

Here's why Centessa Pharma is up 20% on Thursday morning

Centessa Pharmaceuticals PLC – ADR (NASDAQ: CNTA), in partnership with its subsidiary ApcinteX Limited announced that results from its ongoing first-in-human proof-of-concept study to analyze SerpinPC i...

1 month ago - Invezz

Centessa Stock Surges On Positive Data From Hemophilia Candidate

Centessa Pharmaceuticals plc (NASDAQ: CNTA) has announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of the study evaluating SerpinPC in severe hemophi...

1 month ago - Benzinga

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia...

~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~

1 month ago - GlobeNewsWire

Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an ...

1 month ago - GlobeNewsWire

Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates

~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs ~

2 months ago - GlobeNewsWire

Centessa Hits the Market in 3rd Biggest Biotech IPO of the Year

If two heads are better than one, consider what 10 can accomplish. That's the thinking behind Centessa Pharmaceuticals ( CNTA , Financial), a company constructed from the merger of 10 small drug companies.

4 months ago - GuruFocus

Centessa Hits the Market in Third Biggest Biotech IPO of the Year

If two heads are better than one, consider what ten can accomplish.

4 months ago - GuruFocus

Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an...

4 months ago - GlobeNewsWire

Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additiona...

CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, deve...

4 months ago - GlobeNewsWire

Centessa Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Centessa Announces Pricing of Initial Public Offering

4 months ago - Business Wire

Biotech Centessa Pharma hoping for $250M IPO to top January series A and fund initial drug development

Centessa Pharmaceuticals, with four clinical and a dozen preclinical programs, expects its initial public offering to be slightly over the $250 million raised in a January series A. The largest single r...

5 months ago - FierceBiotech

Centessa Pharmaceuticals IPO Registration Document (S-1)

Centessa Pharmaceuticals Limited has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC